{"id":454402,"date":"2021-03-10T01:03:29","date_gmt":"2021-03-10T06:03:29","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454402"},"modified":"2021-03-10T01:03:29","modified_gmt":"2021-03-10T06:03:29","slug":"santhera-completes-capital-increase-for-financing-arrangements","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/santhera-completes-capital-increase-for-financing-arrangements\/","title":{"rendered":"Santhera Completes Capital Increase for Financing Arrangements"},"content":{"rendered":"
\n

\n
\n
Pratteln, Switzerland, March\u00a010, 2021 \u2013 Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 480,708 treasury shares. The number of shares recorded in the commercial register has been increased to 21,510,404 shares.<\/strong>\n <\/p>\n

On March\u00a09, 2021, and as announced when calling the extraordinary general meeting of shareholders scheduled for March\u00a018, 2021, 480,708 shares were issued out of the existing authorized capital as treasury shares. Santhera expects to use these shares for purposes of its financing arrangements. The new shares will be listed as per March\u00a010, 2021.<\/p>\n

\n About Santhera <\/strong>
\n
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical need. Santhera has an exclusive license for all indications worldwide to vamorolone, a first-in-class dissociative steroid with novel mode of action, currently investigated in a pivotal study in patients with DMD as an alternative to standard corticosteroids. The clinical stage pipeline also includes lonodelestat (POL6014) to treat cystic fibrosis (CF) and other neutrophilic pulmonary diseases, as well as an exploratory gene therapy approach targeting congenital muscular dystrophies. Santhera out-licensed ex-North American rights to its first approved product, Raxone\u00ae (idebenone), for the treatment of Leber’s hereditary optic neuropathy (LHON) to Chiesi Group. For further information, please visit www.santhera.com<\/u><\/a>.\u00a0 <\/p>\n

\n Raxone\u00ae<\/sup> is a trademark of Santhera Pharmaceuticals.<\/em>\n <\/p>\n

\n For further information please contact: <\/strong>
\n
\n
\n public-relations@santhera.com<\/u>
\n <\/a> or
Eva Kalias, Head External Communications
Phone: +41 79 875 27 80
eva.kalias@santhera.com <\/u><\/p>\n

\n Disclaimer \/ Forward-looking statements <\/strong>
\n
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.<\/p>\n

# # #<\/p>\n

\n

\n Attachment<\/strong>\n <\/p>\n